Nippon India Pharma Fund
Sectoral-PharmaVery HighOPEN-ENDED
- NAV as on 25 Sep 2026
- ₹572.77-0.36%1 day
- Return since launch
- 19.9%
- 52-week range
- ₹481.82 — ₹581.04
- AUM
- ₹9,479 Cr
Nippon India Pharma Fund is a Sectoral-Pharma equity fund from Nippon India Mutual Fund with ₹9,479 Cr under management, launched in 2004. Over three years it has returned 12.7% a year, against 21.1% for its category. The expense ratio is 1.84% and the SEBI riskometer reading is Very High.
Performance
Nippon India Pharma Fund NAV and returns
Growth of the fund against its category average over the period you pick.
Over 1Y this fund returned +15.0% against +19.5% for its category.
Performance
Returns
How the fund has done against its category and its benchmark.
| Period | Fund | vs category | Category | Benchmark |
|---|---|---|---|---|
| 1Y | 18.6% | −2.3 pts | 20.9% | 26.4% |
| 2Y | 11.2% | −5.6 pts | 16.8% | 15.2% |
| 3Y | 12.7% | −8.4 pts | 21.1% | 15.8% |
| 5Y | 16.8% | +2.5 pts | 14.3% | 18.0% |
| 7Y | 17.9% | −1.3 pts | 19.2% | 18.1% |
| 10Y | 17.8% | +4.2 pts | 13.7% | 16.9% |
| Period | Fund | vs category | Category | Benchmark |
|---|---|---|---|---|
| 1M | -0.5% | −0.7 pts | 0.2% | -0.3% |
| 3M | 3.5% | −2.7 pts | 6.2% | 6.0% |
| 6M | 15.6% | −6.6 pts | 22.1% | 20.9% |
| 1Y | 15.0% | −5.9 pts | 20.9% | 19.5% |
| 2Y | 4.8% | −3.4 pts | 8.2% | 6.5% |
| 3Y | 18.7% | −2.4 pts | 21.1% | 20.1% |
| 5Y | 13.2% | −1.1 pts | 14.3% | 13.4% |
| 7Y | 21.9% | −0.5 pts | 22.4% | 21.3% |
| 10Y | 14.6% | +0.9 pts | 13.7% | 12.2% |
Since launch (10 May 2004): 19.9%
Calendar-year returns
Category average66.4%
23.9%
-9.9%
39.2%
33.7%
-3.3%
Show as a table
| Period | Fund | vs category | Category |
|---|---|---|---|
| 2025 | -3.3% | −1.3 pts | -2.0% |
| 2024 | 33.7% | −7.2 pts | 40.9% |
| 2023 | 39.2% | +2.9 pts | 36.2% |
| 2022 | -9.9% | −1.6 pts | -8.3% |
| 2021 | 23.9% | +2.2 pts | 21.7% |
| 2020 | 66.4% | −2.4 pts | 68.8% |
Returns over one year are annualised. Shorter periods are absolute.
Costs & terms
Costs and terms
What the fund charges each year, and the rules around putting money in and taking it out.
Costs
1.84%
Expense ratio as on 24 Sep 2026
Charged yearly and already deducted from the NAV.
- Base expense
- 1.51%
- Brokerage
- 0.02%
- Transaction charges
- 0.00%
- Statutory levies
- 0.31%
- Exit load
- Exit load of 1% if redeemed within 1 month.
- Lock-in
- None
Terms
- Min SIP
- ₹3,000
- Min lumpsum
- ₹5,000
- Plan
- GROWTH
- Fund type
- OPEN-ENDED
- Benchmark
- BSE Healthcare TRI
- Short-term capital gains
- Returns taxed at 20% if you redeem before 1 year
- Long-term capital gains
- After 1 year, returns above ₹1.25 lakh in a financial year are taxed at 12.5%
Risk
Risk
What the riskometer means for this fund, and how its ratios sit against the category.
Very High
Your principal is treated as being at very high risk — typically small cap, sectoral and thematic equity schemes.
| Ratio | Fund | Category avg | Read as |
|---|---|---|---|
| Alpha | -2.04 | 0.74 | Return earned above what the benchmark alone would have given. Higher is better. |
| Beta | 0.88 | 0.93 | How hard the fund moves when the market moves. Under 1 is steadier than the market. |
| Sharpe | 0.86 | 1.05 | Return earned for each unit of total risk taken. Higher is better. |
| Sortino | 1.27 | 1.63 | Return earned for each unit of downside risk. Higher is better. |
| Std. deviation | 14.76 | 15.68 | How widely monthly returns have varied around their own average. Lower is steadier. |
| Average of 5 category peers | |||
Portfolio
Nippon India Pharma Fund portfolio
Portfolio as of 31 Aug 2026
Asset allocation
- Equity98.0%
- Debt0.0%
- Other2.0%
Market cap split
- Large31.2%
- Mid39.6%
- Small29.2%
- P/E
- 39.80
- P/B
- 5.49
Top holdings
| Holding | Sector | Weight | Value | 3M chg | 6M chg | 1Y chg |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | Healthcare | 12.37% | ₹1,172 Cr | +13.35% | +13.08% | +11.94% |
| Divi's Laboratories Ltd. | Healthcare | 7.00% | ₹663 Cr | +5.80% | +6.56% | +7.34% |
| Lupin Ltd. | Healthcare | 6.43% | ₹609 Cr | +7.31% | +7.99% | +6.09% |
| Cipla Ltd. | Healthcare | 6.09% | ₹577 Cr | +6.16% | +5.67% | +6.09% |
| Apollo Hospitals Enterprise Ltd. | Healthcare | 5.15% | ₹488 Cr | +5.20% | +5.17% | +5.91% |
| Dr. Reddy's Laboratories Ltd. | Healthcare | 4.93% | ₹468 Cr | +6.72% | +5.81% | +5.90% |
| Mankind Pharma Ltd. | Healthcare | 4.09% | ₹388 Cr | +3.94% | +3.06% | +2.24% |
| Sai Life Sciences Ltd. | Healthcare | 3.94% | ₹373 Cr | +3.43% | +3.07% | +2.52% |
| Ajanta Pharma Ltd. | Healthcare | 3.47% | ₹329 Cr | +3.21% | +3.41% | +2.84% |
| Glaxosmithkline Pharmaceuticals Ltd. | Healthcare | 3.31% | ₹314 Cr | +2.34% | +2.83% | +3.04% |
| Max Healthcare Institute Ltd. | Healthcare | 2.92% | ₹277 Cr | +2.97% | +3.49% | — |
| Ipca Laboratories Ltd. | Healthcare | 2.84% | ₹270 Cr | +2.41% | +2.51% | +1.30% |
| Vijaya Diagnostic Centre Ltd. | Healthcare | 2.68% | ₹254 Cr | +3.21% | +3.49% | +3.48% |
| Medplus Health Services Ltd. | Healthcare | 2.51% | ₹238 Cr | +3.68% | +3.70% | +3.65% |
| Thyrocare Technologies Ltd. | Healthcare | 2.45% | ₹232 Cr | +2.56% | +2.08% | +2.63% |
| Gland Pharma Ltd. | Healthcare | 2.44% | ₹231 Cr | +2.09% | +1.76% | +2.96% |
| Piramal Pharma Ltd. | Healthcare | 2.25% | ₹213 Cr | — | — | — |
| Abbott India Ltd. | Healthcare | 2.13% | ₹202 Cr | +2.31% | +2.37% | +2.59% |
| Dr. Lal Pathlabs Ltd. | Healthcare | 2.04% | ₹194 Cr | +1.90% | +2.05% | +2.41% |
| Others | Others | 2.01% | ₹190 Cr | 0.00% | +0.01% | 0.00% |
| Alkem Laboratories Ltd. | Healthcare | 1.82% | ₹173 Cr | +2.06% | +2.20% | +2.05% |
| Narayana Hrudayalaya Ltd. | Healthcare | 1.66% | ₹157 Cr | +1.81% | +1.82% | +2.16% |
| Aurobindo Pharma Ltd. | Healthcare | 1.63% | ₹155 Cr | +2.32% | +2.50% | +2.09% |
| Pfizer Ltd. | Healthcare | 1.57% | ₹149 Cr | +1.69% | +1.94% | +1.96% |
| Syngene International Ltd. | Healthcare | 1.48% | ₹140 Cr | +1.79% | +0.96% | +0.96% |
| Suraksha Diagnostic Ltd. | Healthcare | 1.39% | ₹132 Cr | +1.29% | +1.27% | +1.39% |
| Fortis Healthcare Ltd. | Healthcare | 1.29% | ₹122 Cr | +1.19% | +1.25% | +1.20% |
| Emcure Pharmaceuticals Ltd. | Healthcare | 1.25% | ₹119 Cr | +1.47% | +1.31% | +0.78% |
| Anthem Biosciences Ltd. | Healthcare | 1.20% | ₹114 Cr | +0.93% | +0.89% | +1.04% |
| Akums Drugs And Pharmaceuticals Ltd. | Healthcare | 1.11% | ₹105 Cr | +0.92% | +0.89% | +0.82% |
| Biocon Ltd. | Healthcare | 1.09% | ₹103 Cr | +0.73% | +1.04% | +1.76% |
| Sanofi India Ltd. | Healthcare | 0.99% | ₹93.81 Cr | +0.83% | +1.10% | +1.42% |
| Sanofi Consumer Healthcare India Ltd. | Healthcare | 0.93% | ₹88.46 Cr | +1.14% | +1.15% | +1.33% |
| Indoco Remedies Ltd. | Healthcare | 0.47% | ₹44.65 Cr | +0.45% | +0.45% | +0.59% |
| Astrazeneca Pharma India Ltd. | Healthcare | 0.46% | ₹43.49 Cr | +0.63% | +0.67% | +0.63% |
| company:20769 | Healthcare | 0.44% | ₹41.31 Cr | — | — | — |
| Concord Biotech Ltd. | Healthcare | 0.17% | ₹16.16 Cr | +0.14% | +0.16% | +0.22% |
Sectors
Instruments
Recent changes
| Holding | From | To | Weight |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 13.31% | 12.37% | -0.94% |
| Lupin Ltd. | 7.25% | 6.43% | -0.82% |
| Glaxosmithkline Pharmaceuticals Ltd. | 2.66% | 3.31% | +0.65% |
| Others | 0.51% | 0.01% | -0.50% |
| Divi's Laboratories Ltd. | 6.52% | 7.00% | +0.48% |
| company:20769 | 0.00% | 0.44% | +0.44% |
| Mankind Pharma Ltd. | 3.74% | 4.09% | +0.35% |
| Emcure Pharmaceuticals Ltd. | 1.58% | 1.25% | -0.33% |
| Suraksha Diagnostic Ltd. | 1.06% | 1.39% | +0.33% |
| Sai Life Sciences Ltd. | 3.62% | 3.94% | +0.32% |
| Anthem Biosciences Ltd. | 0.92% | 1.20% | +0.28% |
| Gland Pharma Ltd. | 2.16% | 2.44% | +0.28% |
| Ipca Laboratories Ltd. | 2.57% | 2.84% | +0.27% |
| Vijaya Diagnostic Centre Ltd. | 2.42% | 2.68% | +0.26% |
| Max Healthcare Institute Ltd. | 3.15% | 2.92% | -0.23% |
| Alkem Laboratories Ltd. | 2.01% | 1.82% | -0.19% |
| Medplus Health Services Ltd. | 2.69% | 2.51% | -0.18% |
| Biocon Ltd. | 0.92% | 1.09% | +0.17% |
| Piramal Pharma Ltd. | 2.09% | 2.25% | +0.16% |
| Apollo Hospitals Enterprise Ltd. | 5.30% | 5.15% | -0.15% |
| Narayana Hrudayalaya Ltd. | 1.80% | 1.66% | -0.14% |
| Sanofi Consumer Healthcare India Ltd. | 1.06% | 0.93% | -0.13% |
| Abbott India Ltd. | 2.24% | 2.13% | -0.11% |
| Akums Drugs And Pharmaceuticals Ltd. | 1.00% | 1.11% | +0.11% |
| Astrazeneca Pharma India Ltd. | 0.55% | 0.46% | -0.09% |
| Aurobindo Pharma Ltd. | 1.54% | 1.63% | +0.09% |
| Dr. Reddy's Laboratories Ltd. | 5.01% | 4.93% | -0.08% |
| Fortis Healthcare Ltd. | 1.37% | 1.29% | -0.08% |
| Sanofi India Ltd. | 1.07% | 0.99% | -0.08% |
| Pfizer Ltd. | 1.65% | 1.57% | -0.08% |
| Ajanta Pharma Ltd. | 3.41% | 3.47% | +0.06% |
| Cipla Ltd. | 6.03% | 6.09% | +0.06% |
| Thyrocare Technologies Ltd. | 2.51% | 2.45% | -0.06% |
| Indoco Remedies Ltd. | 0.43% | 0.47% | +0.04% |
| Syngene International Ltd. | 1.46% | 1.48% | +0.02% |
| Dr. Lal Pathlabs Ltd. | 2.05% | 2.04% | -0.01% |
| Concord Biotech Ltd. | 0.17% | 0.17% | 0.00% |
Compare
Similar funds
The rest of the category, so this fund’s numbers have something to sit against.
| Fund | AUM | Expense | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|
| Category average | ₹3,579 Cr | 2.19% | 27.3% | 17.7% | 20.1% |
 ICICI Prudential Healthcare Fund | ₹6,996 Cr | 2.07% | 14.5% | 14.2% | 19.4% |
 SBI Healthcare Opportunities Fund | ₹5,796 Cr | 1.99% | 33.1% | 19.9% | 22.2% |
 Mirae Asset Healthcare Fund | ₹3,555 Cr | 2.03% | 29.9% | 18.4% | 19.7% |
 UTI Healthcare Fund | ₹1,444 Cr | 2.21% | 30.4% | 19.1% | 21.1% |
 LIC MF Healthcare Fund | ₹103 Cr | 2.67% | 28.7% | 16.9% | 17.9% |
About
About this fund
The scheme’s own words, its benchmark and the people running it.
Investment objective
The scheme seeks to generate consistent returns by investing in equity / equity related or fixed income securities of pharma and other associated companies.
Fund managers
- Amber SinghaniaMMS Finance (Mumbai University)Prior to joining the Nippon India AMC, he was associated with Asian Markets Securities Pvt. Ltd.
- Sailesh Raj BhanMr. Bhan is an MBA (Finance) and CFA.Prior to joining Nippon India Mutual Fund, he has worked with Emkay Share & Stock Broker Pvt. Ltd, Shah & Sequeira Invst. Pvt. Ltd, ICFAI- Securities Research Center Analyst - Equity Research.
Tools
Return calculator
What ₹10,000 a month in this fund would have grown to over each period, based on its past returns.
₹
| Over the past | Total investment | Would’ve become | Growth | Returns |
|---|---|---|---|---|
| 6 months15.57% absolute | ₹60,000 | ₹69,342 | 15.57% | |
| 1 year14.99% annualised | ₹1,20,000 | ₹1,30,204 | 8.50% | |
| 3 years18.73% annualised | ₹3,60,000 | ₹4,85,674 | 34.91% | |
| 5 years13.23% annualised | ₹6,00,000 | ₹8,53,475 | 42.25% |
Returns for 1 year and longer are annualised (CAGR); 6-month figures are absolute. Past returns are not a forecast.
How this is calculated
Each monthly instalment grows at the fund’s annualised return ÷ 12 per month until the end of the period, the same formula as our SIP calculator.
The amount compounds once a year at the fund’s CAGR for that period, the same formula as our lumpsum calculator.
Questions
Frequently asked questions
The things people ask about this scheme.
What is the NAV of Nippon India Pharma Fund?
The NAV of Nippon India Pharma Fund is ₹572.77 as on 25 Sep 2026.
What is the expense ratio of Nippon India Pharma Fund?
The expense ratio of Nippon India Pharma Fund is 1.84% per year.
What is the minimum SIP amount for Nippon India Pharma Fund?
You can start a SIP in Nippon India Pharma Fund with ₹3,000 a month.
What returns has Nippon India Pharma Fund given?
Nippon India Pharma Fund has returned 18.6% over 1 year, 12.7% over 3 years and 16.8% over 5 years (annualised).
Is there a lock-in or exit load on Nippon India Pharma Fund?
Lock-in: None. Exit load: Exit load of 1% if redeemed within 1 month..
How risky is Nippon India Pharma Fund?
Nippon India Pharma Fund is rated Very High on the SEBI riskometer and belongs to the Sectoral-Pharma category.
Which fund house manages Nippon India Pharma Fund?
Nippon India Pharma Fund is managed by Nippon India Mutual Fund, which runs 75 schemes with ₹7,67,506 Cr under management.